Helaina

Helaina

Replicates human proteins as dietary supplements

Overview

Helaina creates advanced nutritional supplements by using a platform that replicates functional human proteins so they can be taken as nutrients. Its flagship product, Effera™, is a replicated version of Human Lactoferrin, a protein found in the body that supports gut health, iron use, and immune function. The protein-based supplement is intended for health-conscious consumers who want science-backed, high-quality ingredients beyond basic nutrition. Unlike typical supplement companies that source standard nutrients, Helaina focuses on producing bioactive proteins as dietary ingredients through its proprietary technology. The company's goal is to improve overall health and vitality by making these human-like proteins available as accessible supplements.

About Helaina

Simplify's Rating
Why Helaina is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Food & Agriculture

Biotechnology

Healthcare

Consumer Goods

Company Size

51-200

Company Stage

Series B

Total Funding

$69.6M

Headquarters

New York City, New York

Founded

2019

Get referred to Helaina

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Helaina says effera achieved U.S. GRAS status, clearing food and supplement commercialization.
  • Nestlé's June 2026 multi-year partnership expands Helaina's route into infant nutrition.
  • 2026 gut-barrier data strengthened effera's case against bovine lactoferrin and supported premium positioning.

What critics are saying

  • Europe approval remains in progress, delaying infant-formula launches outside the United States.
  • Infant formula commercialization depends on regional clinical-trial rules, stretching timelines across markets.
  • Bovine lactoferrin incumbents and ingredient giants can undercut pricing before Helaina reaches scale.

What makes Helaina unique

  • Effera is the first commercial human-identical lactoferrin, matching breast-milk structure exactly.
  • Helaina built precision fermentation around human bioactives, not commodity proteins, protecting scientific differentiation.
  • Nestlé chose Helaina for early-life nutrition research, validating its platform with a blue-chip customer.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$69.6M

Above

Industry Average

Funded Over

4 Rounds

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Above Average

Industry standards

$35M
$45M
Linktree
$45M
Helaina
$65M
Substack
$100M
ClickUp

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

401(k) Company Match

Unlimited Paid Time Off

Paid Parental Leave

Childcare Support

Commuter Benefits

Leadership Development coaching through BetterUp

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-3%

2 year growth

2%
Yahoo Finance
Jun 5th, 2026
Nestlé partners with US biotech Helaina to develop infant formula with precision-fermented proteins

Nestlé has announced a multi-year partnership with Helaina, a New York-based startup that develops proteins through precision fermentation. The collaboration will focus on understanding bioactive proteins and their role in early-life development for infant formula. Helaina's first product is Effera, a lactoferrin bioidentical to the human form found in breast milk and colostrum. The Swiss company, one of the world's largest infant-formula manufacturers, said the partnership forms part of its open innovation strategy to deepen scientific understanding whilst gaining access to emerging technologies. Helaina founder Laura Katz said the company is focused on manufacturing bioactives at scale with clinical credibility. No further details on the contract length were disclosed.

Femtech Insider
Jun 2nd, 2026
Nestlé partners with Helaina to advance bioactive protein research in infant nutrition.

Nestlé partners with Helaina to advance bioactive protein research in infant nutrition. Nestlé and Helaina, the US-based nutrition biotech company, have formed a multi-year strategic innovation collaboration focused on understanding new bioactive proteins and their role in early-life development. The partnership combines Nestlé's 30+ years of research in human milk oligosaccharides and bioactives with Helaina's biotechnology capabilities in manufacturing human-identical proteins. Helaina's first ingredient, effera, is the world's first human-identical lactoferrin - a bioactive that supports iron balance, immune function, and gut health, with superior bioavailability to cow-based alternatives. Founded in 2019 by food scientist Laura Katz, the company has positioned itself at the intersection of precision fermentation and maternal/infant nutrition. "We believe new bioactive proteins present a significant innovation in nutrition right now," said Katz. "At Helaina, we're focused on manufacturing these bioactives at scale with clinical credibility and together with Nestlé we can uncover new developments that advance early-life nutrition." The collaboration is part of Nestlé's broader open innovation strategy to translate scientific insights into nutritional solutions, particularly around interactions between key nutrients, the gut microbiome, and the immune system during early life.

Foovo
Jul 22nd, 2025
Helaina Advances with Precision Fermentation Products

Startups are emerging globally to mass-produce the rare protein human lactoferrin using microbial precision fermentation. In the U.S., several consumer products using precision-fermented human lactoferrin have already launched. Companies like Australia's Eclipse Ingredients, U.S.-based Helaina, and Portugal's PFx Biotech are advancing with funding in the millions to expand the human-derived lactoferrin market.

Business Wire
Sep 26th, 2024
Helaina Raises $45 Million in Series B Funding to Accelerate the Commercialization of Human Bioactive Proteins Starting with effera™ Human Lactoferrin

Helaina, the biotechnology company transforming nutrition with human equivalent bioactive proteins, announced today it has raised $45 million in Serie

NutraIngredients-USA
Aug 24th, 2023
NutraCast: Helaina charts new territory with breast milk proteins from precision fermentation

The biotech company is writing the safety playbook on novel bioactive proteins and to help with this, Helaina hired a nutritional sciences and regulatory affairs veteran, Ross Peterson, PhD, Helaina's new Director of Regulatory Affairs.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Helaina right now.

Find jobs on Simplify and start your career today

We update Helaina's jobs every few hours, so check again soon! Browse all jobs →